Group 1 - The first sublingual nerve stimulation implant surgery in China was completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team, resulting in a notable reduction in apnea episodes and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for Levonorgestrel tablets from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss therapy for overweight and obese individuals, addressing urgent treatment needs and filling a market gap if successful [4] Group 5 - New Element Pharmaceuticals submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]

Group 1 - The first sublingual nerve stimulation implant surgery in China was successfully completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team and resulted in a notable reduction in breathing pauses and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for "Levonorgestrel Tablets" from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss solution for overweight and obese individuals, addressing urgent treatment needs and filling a market gap left by existing GLP-1 drugs [4] Group 5 - New Element Pharmaceuticals submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline that includes ABP-671 and ABP-745 [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]

Core Viewpoint - The approval of Fluorobiphenyl Ester Injection and Levonorgestrel Tablets marks significant advancements for the company in expanding its product pipeline and enhancing its market presence in the pharmaceutical industry [1][4]. Group 1: Fluorobiphenyl Ester Injection - The company’s subsidiary, Yichang Renfu Pharmaceutical, received the drug registration certificate for Fluorobiphenyl Ester Injection from the National Medical Products Administration [1]. - The injection is a non-steroidal analgesic suitable for postoperative and cancer pain management, with a cumulative R&D investment of approximately RMB 35 million [2]. - The projected national sales for Fluorobiphenyl Ester Injection in 2024 are around RMB 980 million, with major competitors including Beijing Tide Pharmaceutical and Wuhan Yanda Medical Nutrition Science [2]. - The approval allows the company to sell the product in the domestic market, which is expected to positively impact its business [2]. Group 2: Levonorgestrel Tablets - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical, received the drug registration certificate for Levonorgestrel Tablets from the National Medical Products Administration [4]. - Levonorgestrel Tablets are indicated for emergency contraception, with a cumulative R&D investment of approximately RMB 13.5 million [5]. - The projected national sales for Levonorgestrel Tablets in 2024 are around RMB 1.14 billion, with key competitors including China Resources Zizhu Pharmaceutical and Gedeon Richter Plc [5]. - The approval signifies the company’s eligibility to market the product domestically, which is anticipated to further enrich its product line and positively influence its financial performance [5].

Group 1 - China Shenhua reported coal sales of 37.5 million tons in August, a year-on-year decrease of 3.1%, with total sales for the first eight months at 280 million tons, down 9.2% year-on-year [1] - China Shenhua, established in November 2004, focuses on coal and electricity production and sales, as well as transportation and coal-to-olefins [1] - Huaren Shuanghe's subsidiary received a drug registration certificate for a new injection used in treating non-ST elevation acute coronary syndrome [1] - Huaren Shuanghe, founded in May 1997, operates in chronic disease management, specialty business, and infusion business [1] Group 2 - New Wufeng's subsidiary signed a property transaction contract for a 60% equity transfer at a price of 9.7 million yuan [1] - New Wufeng, established in June 2001, specializes in pig farming, meat sales, and feed processing [2] - Yaoshi Technology announced that its convertible bonds will stop conversion after September 17, with remaining bonds to be redeemed at 100.62 yuan per bond [3] - Yaoshi Technology, founded in December 2006, focuses on drug molecular building blocks and related services [3] Group 3 - Newhua Co. announced a board member's plan to reduce holdings by up to 75,200 shares, representing 0.039% of total shares [4] - Newhua Co., established in September 1997, specializes in fine chemical products [4] - Hefei Construction's subsidiary signed a land use rights transfer contract for residential land with a total price of 12.24 billion yuan [6] - Hefei Construction, founded in September 1999, is involved in real estate development and property management [6] Group 4 - Guoyao Modern's subsidiary received a drug registration certificate for an injection used in anesthesia and emergency treatment [7] - Guoyao Modern, established in November 1996, focuses on pharmaceutical product development and sales [7] - Maohua Shihua announced the resignation of its deputy general manager [8] - Maohua Shihua, founded in October 1988, specializes in petrochemical products [9] Group 5 - Zhejiang Xineng applied for enforcement of a civil mediation agreement, seeking 170 million yuan from a group for breach of contract [10] - Zhejiang Xineng, established in December 1991, focuses on renewable energy projects [10] - Zejing Pharmaceutical announced the initiation of key clinical trials for a new drug targeting DLL3 [11] - Zejing Pharmaceutical, founded in March 2009, specializes in the development and production of new chemical and biological drugs [12] Group 6 - Huayi Technology's deputy general manager resigned due to personal work arrangements [13] - Huayi Technology, established in December 1998, focuses on high polymer materials and equipment manufacturing [13] - Luxiao Technology's subsidiary signed a strategic cooperation agreement with a leading cross-border e-commerce company [14] - Luxiao Technology, founded in May 1989, operates in various sectors including photovoltaic power generation [14] Group 7 - Aoxiang Pharmaceutical's subsidiary received a drug registration certificate for a new cancer treatment [15] - Aoxiang Pharmaceutical, established in April 2010, focuses on the development and production of pharmaceutical products [15] - Baiyunshan's pharmaceutical factory received approval for five drug supplement applications [16] - Baiyunshan, founded in September 1997, specializes in the research and production of various pharmaceutical products [16] Group 8 - Renfu Pharmaceutical's subsidiaries received drug registration certificates for two new products [17] - Renfu Pharmaceutical, established in March 1993, focuses on drug research and production [18] - China Shipbuilding Technology signed a significant contract for green methanol sales, potentially worth up to 1.2 billion dollars [19] - China Shipbuilding Technology, founded in May 1997, specializes in wind and solar resource development [19] Group 9 - Haohua Technology received a project designation from a global automotive brand for its ADAS system [20] - Haohua Technology, established in January 2010, focuses on intelligent driving perception systems [20] - Hendi Pharmaceutical received approval for a new raw material drug [21] - Hendi Pharmaceutical, founded in December 1995, specializes in chemical raw materials and formulations [22] Group 10 - JX Communication's subsidiary received a temporary use permit for an air traffic communication system [23] - JX Communication, established in January 1995, focuses on communication technology applications [23] - Longyuan Technology's deputy general manager resigned due to work reasons [24] - Longyuan Technology, founded in December 1998, specializes in energy-saving and environmental protection [25] Group 11 - Jiuqiang Bio received a medical device registration for a gastrin-17 assay kit [26] - Jiuqiang Bio, established in January 2001, focuses on in vitro diagnostic testing platforms [26] - Rifei Co. received approval for a stock issuance to specific investors [27] - Rifei Co., founded in December 2009, specializes in special equipment cables and other electrical devices [27] Group 12 - Huayi Media received a subsidy for a micro-short drama project [28] - Huayi Media, established in August 1998, focuses on film and game content investment [28] - Huilong Pharmaceutical's subsidiary received overseas marketing approvals for multiple products [29] - Huilong Pharmaceutical, founded in October 2010, specializes in innovative and high-quality generic drugs [29] Group 13 - Junsheng Electronics' subsidiary received project designations from two major automotive brands [30] - Junsheng Electronics, established in August 1992, focuses on automotive parts [30] - Silek signed an investment cooperation agreement for a new energy project [31] - Silek, founded in January 2004, specializes in metal packaging equipment [31] Group 14 - ST Huhuwa received drug registration certificates for two new products [32] - ST Huhuwa, established in June 2005, focuses on drug research and production [32] - Canray Technology announced a share buyback plan of 20 to 40 million yuan [33] - Canray Technology, founded in September 2005, specializes in integrated circuits [33] Group 15 - Qilu Bank's directors plan to collectively increase their holdings by at least 3.5 million yuan [34] - Qilu Bank, established in June 1996, focuses on corporate and personal banking services [34] - China Overseas Land reported a significant decrease in contract sales in August [35] - China Overseas Land, founded in September 1997, specializes in tourism and real estate [35] Group 16 - Longjian Co. plans to acquire 100% of Guangdong Zhimao's equity for 40,000 yuan [36] - Longjian Co., established in January 1993, focuses on infrastructure construction [36] - Lichong Group's subsidiary received project designations from a luxury car brand [37] - Lichong Group, founded in July 1998, specializes in aluminum alloy products [37] Group 17 - Kanglong Huacheng's subsidiary passed an FDA inspection [38] - Kanglong Huacheng, established in July 2004, focuses on integrated drug research and development services [38] - Kangtai Bio received a drug registration certificate for a new polio vaccine [39] - Kangtai Bio, founded in September 1992, specializes in vaccine development and production [39] Group 18 - Baiyunshan's pharmaceutical factory's drug entered a key clinical trial phase [40] - Baiyunshan, established in September 1997, focuses on various pharmaceutical products [40] - Zhongyuan Home's chairman plans to reduce holdings by up to 3% [41] - Zhongyuan Home, founded in November 2001, specializes in furniture production [41] Group 19 - Shangluo Electronics plans to acquire 88.79% of Ligon Technology's equity for 709 million yuan [42] - Shangluo Electronics, established in August 1999, focuses on electronic components [42] - Shangluo Electronics also plans to issue convertible bonds to raise 1 billion yuan [43] - Shangluo Electronics, founded in August 1999, specializes in electronic products for various applications [43] Group 20 - HNA Holdings reported a 3.38% increase in passenger capacity in August [44] - HNA Holdings, established in December 1995, focuses on air transportation services [44] - Yipin Hong's subsidiary received a drug registration certificate for a new product [45] - Yipin Hong, founded in February 2002, specializes in pharmaceutical production [45] Group 21 - Haishi Ke's innovative drug received approval for a new indication [46] - Haishi Ke, established in August 2005, focuses on new drug development [46] - Huaxia Airlines plans to repurchase shares worth 80 to 160 million yuan [47] - Huaxia Airlines, founded in April 2006, specializes in air transportation services [47] Group 22 - Jingchen Co. plans to acquire 100% of Xinchip Microelectronics for 316 million yuan [48] - Jingchen Co., established in July 2003, focuses on semiconductor design [48] - Zhongxin Heavy Industry was recognized as an excellent smart factory by the Ministry of Industry and Information Technology [49] - Zhongxin Heavy Industry, founded in January 2008, specializes in large equipment and technology solutions [49]

每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 曾健辉） 每经AI快讯，人福医药（SH 600079，收盘价：22.24元）9月16日晚间发布公告称，人福医药集团股份 公司控股子公司武汉九珑人福药业有限责任公司近日收到国家药品监督管理局核准签发的左炔诺孕酮片 的《药品注册证书》。产品名称为"左炔诺孕酮片"。 2024年1至12月份，人福医药的营业收入构成为：医药占比56.01%，医药批发及相关业占比43.8%，其 他业务占比0.19%。 截至发稿，人福医药市值为363亿元。 ...

Core Viewpoint - The approval of Levonorgestrel tablets by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell this emergency contraceptive in the domestic market, which is expected to positively impact its product line and overall business performance [1]. Group 1 - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Levonorgestrel tablets [1]. - Levonorgestrel tablets are indicated for emergency contraception in women [1]. - The approval enhances the company's product portfolio, which is anticipated to bring positive effects on its sales and market presence [1].

每经AI快讯，9月16日，人福医药（600079）(600079.SH)公告称，公司控股子公司武汉九珑人福药业有 限责任公司收到国家药品监督管理局核准签发的左炔诺孕酮片的《药品注册证书》。该药品适用于女性 紧急避孕，九珑人福于2024年5月提交申请并获得受理，累计研发投入约为1350万元。根据米内网数 据，2024年度左炔诺孕酮片全国销售额约为11.4亿元。 ...